방사선종양학

본문글자크기
  • 2024년 05월호
    [Cancer Diagn Progn .] Clinical Outcomes in Patients With DLBCL Treated With R-CHOP According to Radiotherapy and Interim PET Response

    고신의대 / 유제상, 정성의, 김다정*

  • 출처
    Cancer Diagn Progn .
  • 등재일
    2024 Mar 3
  • 저널이슈번호
    4(2):172-181. doi: 10.21873/cdp.10304. eCollection 2024 Mar-Apr.
  • 내용

    바로가기  >

    Abstract
    Background/aim: Interim positron emission tomography/computed tomography (PET/CT) scan is a valuable tool for assessing the early metabolic response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). Although radiotherapy is an effective treatment for lymphoma, especially for local tumor control, the role of consolidative radiotherapy in diffuse large B-cell lymphoma (DLBCL) remains controversial. This study analyzed the clinical outcomes of patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), stratified by interim PET response and the administration of radiotherapy.

    Patients and methods: We conducted a retrospective review of 107 patients with DLBCL treated with R-CHOP chemotherapy between January 2012 and December 2016. Overall survival (OS), recurrence-free survival (RFS), and freedom from disease progression (FFDP) were calculated using the Kaplan-Meier method and compared using the log-rank test.

    Results: Forty-six patients were included in this analysis, with a median follow-up time of 65.9 months (range=4.7-125.3 months). The metabolic CR (mCR) group exhibited superior OS, RFS, and FFDP compared with the metabolic PR (mPR) group (p=0.003, p=0.001, and p=0.008, respectively). The 1-, 2-, and 5-year FFDP were 92.97%, 89.3%, and 85.6%, respectively, in the mCR group and 78.6%, 61.9%, and 44.2%, respectively, in the mPR group. In subgroup analysis, the FFDP of the mPR group without radiotherapy was significantly lower than that of the other groups (mCR with/without radiotherapy and mPR with radiotherapy, p=0.001).

    Conclusion: Consolidative radiation therapy using interim PET can benefit patients who do not achieve mCR. Further well-controlled prospective randomized trials are required.

     

     

    Affiliations

    Jesang Yu # 1, Sung Ui Jung # 2, Jin Hyuk Choi 2, Sungmin Jun 3, Ho Sup Lee 4, Dajung Kim 4
    1Department of Radiation Oncology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
    2Department of Surgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
    3Department of Nuclear Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
    4Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
    #Contributed equally.

  • 키워드
    Diffuse large B cell lymphoma; consolidation; consolidative radiation therapy; early response; interim PET/CT; radiotherapy.
  • 편집위원

    DLBCL환자들에 대해 R-CHOP 으로 치료받은 후, PET/CT반응과 방사선치료를 함께 분석함. 총 107명을 대상으로 후향적 분석을 시행하고, 46명 환자를 포함하여 분석함. mCR그룹이 임상적 예후가 매우 우수한 것으로 재확인되었으며, 방사선치료를 받지않은 mPR그룹이 모든 그룹 중 유의하게 나쁜 성적을 보임.

    덧글달기2024-05-03 14:29:44

  • 편집위원2

    본 논문은 chemotherapy(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP))를 수행한 DLBCL 환자들에서 radiotherapy와 interim PET response에 따라 그룹화하여 다각적으로 분석하고 그 결과들을 바탕으로 환자들의 예후에 대한 임상적 의미를 시사하고 있음으로 학술적 가치가 높고 DLBCL 환자 치료 연구에 중요한 참고 문헌이 될 수 있을 것이다.

    덧글달기2024-05-03 14:38:05

  • 덧글달기
    덧글달기
       IP : 35.170.81.33

    등록